|Bid||11.40 x 1100|
|Ask||11.57 x 4000|
|Day's Range||11.27 - 12.36|
|52 Week Range||4.71 - 19.47|
|Beta (5Y Monthly)||1.34|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jun 29, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||43.33|
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today announced the launch of its new research and development lab facility in New York City. This new research facility expands Actinium's internal R&D capabilities and will be focused on developing novel Antibody Radiation Conjugate (ARC) candidates, ARC therapeutic combination strategies, and supporting AWE platform research collaborations. Actinium's R&D efforts will employ a multidisciplinary approach leveraging its team's expertise and experience in cancer cell biology, radiochemistry, radiation sciences, immunology and oncology drug development. The proprietary AWE technology platform, protected by over one hundred and twenty-five patents, is the foundation for Actinium's R&D and exploits multiple different radioisotope payloads including the potent alpha-emitter, Actinium-225.
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
In the latest trading session, Actinium Pharmaceuticals (ATNM) closed at $10.15, marking a +1.2% move from the previous day.